Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.

Source:http://linkedlifedata.com/resource/pubmed/id/15824414

J. Clin. Oncol. 2005 May 20 23 15 3404-11

Download in:

View as

General Info

PMID
15824414